Search our Database of Scientific Publications and Authors

I’m looking for a

    2405 results match your criteria Cutaneous B-Cell Lymphoma

    1 OF 49

    Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    J Clin Oncol 2017 Apr 20:JCO2017726984. Epub 2017 Apr 20.
    Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis; Diderot University, Sorbonne Paris-Cité; Catherine Thieblemont and Josette Briere, Descartes University; Josette Briere, Hôpital Necker, Paris; Hervé Tilly, University of Rouen, Institut National de la Santé et de la Recherche Médicale U1245, Rouen; Rene-Olivier Casasnovas, Centre Hospitalier Universitaire Dijon; Institut National de la Santé et de la Recherche Médicale UMR1231, Dijon; Christophe Fruchart, Institut d'Hématologie de Basse Normandie, Centre Hospitalier Universitaire, Caen; Franck Morschhauser, Centre Hospitalier Universitaire Régional de Lille, Lille; Corinne Haioun and Philippe Gaulard, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Mondor; Philippe Gaulard, Institut National de la Santé et de la Recherche Médicale U955; Université Paris-Est, Créteil; Julien Lazarovici, Gustave Roussy Cancer Center, Villejuif; Aurore Perrot, University Hospital, Vandoeuvre les Nancy; Catherine Sebban, Centre Leon Berard, University Claude Bernard Lyon 1; Gilles Salles, Hospices Civils de Lyon, Université Claude Bernard U1052, Lyon; Hugo Gonzalez, Centre Hospitalier René Dubos, Pontoise; Reda Bouabdallah, Institut Paoli Calmettes, Marseille; Lucie Oberic, Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse; Bernadette Corront, Centre Hospitalier Régional Annecy, Annecy; Bachra Choufi, Centre Hospitalier Dr Duchenne, Boulogne-sur-mer; Gilles Salles and Bertrand Coiffier, Institut National de la Santé et de la Recherche Médicale U1052, Hospices Civils de Lyon, Pierre-Benite, France; Maria Gomes da Silva and Jose Cabeçadas, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal; Anida Grosicka, Medical University of Silesia, Katowice, Poland; Judith Trotman, Concord Repatriation General Hospital, University of Sydney, Concord; John Catalano, Frankston Hospital and Monash University, Frankston, Australia; Dolores Caballero, Hospital Universitario de Salamanca, Salamanca; Armando Lopez-Guillermo, Hospital Clinic Barcelona, Barcelona, Spain; Richard Greil, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria; Koen van Eygen, Algemeen Ziekenhuis Groeninge Hospital, President Kennedylaan 4, Kortrijk; Achiel Van Hoof, Algemeen Ziekenhuis Sint Jan AV, Brugge; Andre Bosly, UCL Mont Godinne, Yvoir, Belgium; and Amos M. Cohen, Rabin Medical Center, Beilinson Hospital, Davidoff Cancer Center, Tel-Aviv University, Ramat-Aviv, Israel.
    Purpose The standard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Lenalidomide, an immunomodulatory agent, has shown activity in DLBCL. This randomized phase III trial compared lenalidomide as maintenance therapy with placebo in elderly patients with DLBCL who achieved a complete response (CR) or partial response (PR) to R-CHOP induction. Read More

    A Literature Revision in Primary Cutaneous B-cell Lymphoma.
    Indian J Dermatol 2017 Mar-Apr;62(2):146-157
    Department of Medical Sciences, Dermatologic Clinic, University of Turin, Turin, Italy.
    The term "Primary Cutaneous B-Cell Lymphoma" (PCBCL) comprehends a variety of lymphoproliferative disorders characterized by a clonal proliferation of B-cells primarily involving the skin. The absence of evident extra-cutaneous disease must be confirmed after six-month follow-up in order to exclude a nodal non-Hodgkin's lymphoma (NHL) with secondary cutaneous involvement, which may have a completely different clinical behavior and prognosis. In this article, we have summarized the clinico-pathological features of main types of PCBCL and we outline the guidelines for management based on a review of the available literature. Read More

    Erythema ab igne: new technology rebounding upon its users?
    Int J Dermatol 2017 Mar 30. Epub 2017 Mar 30.
    Dermatology and Pathology, Rutgers New Jersey Medical School, Rutgers University School of Public Affairs and Administration, Newark, NJ, USA.
    Erythema ab igne (EAI) is a persistent, chronic skin condition resulting from prolonged exposure to infrared radiation, experienced as heat. Once associated with traditional warming sources like wood burning stoves or open fires, modern, infrared exposure originates also from newer sources like laptops and heating pads and may be creating a rebound of EAI. The epidemiology may be different too, with younger patients than previously seen. Read More

    Nationwide Statistical Analysis of Lymphoid Malignancies in Korea.
    Cancer Res Treat 2017 Mar 30. Epub 2017 Mar 30.
    Cancer Registration and Statistics branch, National Cancer Center, Goyang, Korea.
    Purpose: Regional differences in the incidence of lymphoid malignancies have been reported worldwide, but there has been no large-scale epidemiologic analysis in Korea. The aim of this study was to provide a nationwide population-based statistical analysis of Korean patients with lymphoid malignancies.

    Materials And Methods: The Korea Central Cancer Registry analyzed the incidence and survival of patients with lymphoid malignancies from the Korean National Cancer Incidence Database. Read More

    Chronic lymphocytic leukemia skin infiltration mimicking an ICD pocket infection: a case report.
    BMC Cardiovasc Disord 2017 Mar 24;17(1):89. Epub 2017 Mar 24.
    Department of Hematology, Ceske Budejovice Hospital, Ceske Budejovice, Czech Republic.
    Background: We are presenting a case report on an unreported and unusual cutaneous manifestation of chronic lymphocytic leukemia in a patient with an implantable cardioverter-defibrillator (ICD).

    Case Presentation: A 65-year-old man with a history of chronic lymphocytic leukemia (CLL), previously treated with chlorambucil, was referred in October 2013 for extraction of a single chamber ICD due to a suspected device-related infection in the pulse generator area (left-hand side of Fig. 1). Read More

    Primary cutaneous anaplastic large cell lymphoma with intralymphatic involvement associated with chronic lymphedema.
    J Cutan Pathol 2017 Mar 23. Epub 2017 Mar 23.
    Department of Dermatology and Venerology, Peking University First Hospital, Beijing, 100034, China.
    Chronic lymphedema predisposes to develop malignant cutaneous tumors, including angiosarcoma, Kaposi's sarcoma and B cell lymphoma. T cell malignancy has rarely been associated with chronic lymph stasis. Here we report a case of primary cutaneous anaplastic large cell lymphoma (pcALCL) with lymphatic spread associated with chronic lymphedema. Read More

    Primary cutaneous spindle cell B cell lymphoma: A report of three cases and review of the literature.
    Ann Diagn Pathol 2017 Apr 23;27:18-23. Epub 2016 Nov 23.
    Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
    Primary cutaneous spindle cell lymphoma is a rare variant of primary cutaneous B-cell lymphoma (PCBCL). Herein, we present 3 cases of primary cutaneous spindle cell B cell lymphoma, 2 males and one female (age range 66-76years). The patients presented with solitary skin lesions, distributed in the head and neck area and chest. Read More

    Diffuse large B-Cell lymphoma developing in erythrodermic cutaneous T-cell lymphoma: a case series.
    Br J Dermatol 2017 Mar 16. Epub 2017 Mar 16.
    St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
    Mycosis fungoides (MF) and its leukemic form, Sezary Syndrome (SS), are the most common forms of cutaneous T-cell lymphoma (CTCL). CTCL is associated with an increased risk of secondary cancers, including lymphomas.(1) Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma (NHL) in the western world and can involve both nodal and extranodal sites including the skin. Read More

    Clinical Applications of the Genomic Landscape of Aggressive Non-Hodgkin Lymphoma.
    J Clin Oncol 2017 Mar 13;35(9):955-962. Epub 2017 Feb 13.
    Andrea B. Moffitt and Sandeep S. Dave, Duke University, Durham, NC.
    In this review, we examine the genomic landscapes of lymphomas that arise from B, T, and natural killer cells. Lymphomas represent a striking spectrum of clinical behaviors. Although some lymphomas are curable with standard therapy, the majority of the affected patients succumb to their disease. Read More

    A 92-year-old man with primary cutaneous diffuse large B-cell non-Hodgkin's lymphoma manifesting as a giant scalp mass: A case report.
    Medicine (Baltimore) 2017 Mar;96(10):e6270
    Department of Neurosurgery, XinHua Hospital affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, P.R. China.
    Rationale: Primary cutaneous non-Hodgkin's lymphoma (NHL) is an uncommon entity, representing 10% of all extranodal NHLs. Among all cutaneous sites, the scalp is a rare site of representation.

    Patient Concerns: A 92-year-old Chinese man visited our hospital with a multiple-nodular huge scalp mass on the right parieto-occipital regions. Read More

    Primary cutaneous diffuse large B cell lymphoma-other successfully treated by the combination of R-CHOP chemotherapy and surgery: A case report and review of literature.
    Medicine (Baltimore) 2017 Feb;96(8):e6161
    aDepartment of Dermatology, The Second Affiliated Hospital of Xi'an Jiaotong University, School of Medicine bDepartment of Pathology, Shaanxi Provincial People's Hospital, The Third Affiliated Hospital of Xi'an Jiaotong University, School of Medicine, Xi'an, China.
    Rationale: The occurrence of primary cutaneous diffuse large B cell lymphoma-other (PCDLBCL-O) has been rarely reported in the literature. Its diagnosis is based on histopathological and immunohistochemical examinations. To improve the clinical diagnosis and treatment for PCDLBCL-O, we report a case of PCDLBCL-O successfully treated by the combination of R-CHOP (A chemotherapy protocol consists of cyclophosphamide, doxorubicin, vincristine, prednisone plus Rituximab) chemotherapy and surgery. Read More

    A Rare Case of CK20/CK7 Double Negative Merkel Cell Carcinoma.
    Am J Dermatopathol 2017 Mar;39(3):208-211
    *Department of Pathology, University of California Los Angeles, Los Angeles, CA; †Southern California Permanente Medical Group, Department of Dermatology, Sunset Medical Center, Los Angeles, CA; and ‡Department of Pathology, Kaiser Southern California Permanente Medical Group, Los Angeles, CA.
    The authors present a case of Merkel cell carcinoma (MCC) with unique immunohistochemical staining characteristics. A 57-year-old woman presented with a firm 0.3 cm tan papule on her left nasal-labial fold that was reportedly increasing in size and bleeding. Read More

    Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines.
    Tumori 2017 Feb 14. Epub 2017 Feb 14.
    Radiation Oncology Department, Azienda Ospedaliera Spedali Civili di Brescia and Brescia University, Brescia - Italy.
    Purpose: To analyze clinical outcome, local response, survival and toxicity in patients with primary cutaneous lymphoma (PCL) treated with radiotherapy.

    Methods: From 1995 to 2014, 112 patients were treated. B-cell lymphomas (CBCLs; n = 86) and T-cell lymphomas (CTCLs; n = 23) were analyzed separately. Read More

    MCL-1 is modulated in Crohn's disease fibrosis by miR-29b via IL-6 and IL-8.
    Cell Tissue Res 2017 May 11;368(2):325-335. Epub 2017 Feb 11.
    Centre for Genomics and Child Health and National Centre for Bowel Research, Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, Whitechapel, E1 2AT, London, UK.
    The miR-29 family is involved in fibrosis in multiple organs, including the intestine where miR-29b facilitates TGF-β-mediated up-regulation of collagen in mucosal fibroblasts from Crohn's disease (CD) patients. Myeloid cell leukemia-1 (MCL-1), a member of the B-cell CLL/Lymphoma 2 (BCL-2) apoptosis family, is involved in liver fibrosis and is targeted by miR-29b via its 3'-UTR in cultured cell lines. We investigate the role of MCL-1 and miR-29b in primary intestinal fibroblasts and tissue from stricturing CD patients. Read More

    Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
    J Dtsch Dermatol Ges 2017 Mar 8;15(3):319-323. Epub 2017 Feb 8.
    Department of Dermatology, Eberhard Karls University, Tübingen, Germany.
    Background And Objectives: Intralesional injection of anti-CD20 antibody (rituximab) has been described as effective therapeutic option for patients with indolent primary cutaneous B-cell lymphoma (PCBL). To date, no parameters that reproducibly predict favorable clinical outcome of this treatment have been identified. The study aims to evaluate the clinical response and adverse effects as well as patients' self-perception of intralesional injection of anti-CD20 antibody for treatment of indolent PCBL compared to other treatment modalities. Read More

    Retrospective study of intravascular large B-cell lymphoma cases diagnosed in Quebec: A retrospective study of 29 case reports.
    Medicine (Baltimore) 2017 Feb;96(5):e5985
    aDepartment of Hematology-Oncology at Sherbrooke University Hospital Center, CIUSSS Estrie, University of Sherbrooke, Sherbrooke bDepartment of Pathology at Sherbrooke University Hospital Center, CIUSSS Estrie, University of Sherbrooke, Sherbrooke cDepartment of Hematology-Oncology at McGill University Health Centre, CIUSSS Centre-Ouest-de-l'Île-de-Montréal, McGill University, Montreal dDepartment of Pathology at Laval University Hospital Center, CIUSSS Capitale Nationale, University Laval, Quebec eDepartment of Hematology-Oncology at Chicoutimi Hospital, CIUSSS Saguenay-Lac-Saint-Jean, University of Sherbrooke, Chicoutimi fDepartment of Pathology at Montreal University Hospital Center, CIUSSS Est-de-l'Île-de-Montréal, University of Montreal, Montreal gDepartment of Pathology at Charles-Lemoyne Hospital, CIUSSS Montérégie-Centre, University of Sherbrooke, Longueuil hDepartment of Pathology at Cité-de-la-Santé Hospital, CIUSSS Laval, Laval iDepartment of Hematology-Oncology at Montreal University Hospital Center in Trois-Rivières, CIUSSS Mauricie-et-du-Centre-du-Québec, Trois-Rivieres jDepartment of Hematology-Oncology at Maisonneuve-Rosemont Hospital, CIUSSS Est-de-l'Île-de Montréal, University of Montreal, Montreal, Quebec, Canada.
    Introduction: Intravascular large B-cell lymphoma (IVL) is an extremely rare malignancy, mainly studied through European and Asian series. Due to the low incidence of this condition, our understanding of the clinical presentation as well as the management of IVL relies on a limited number of patients.We report the largest North American study to date on IVL with 29 cases from Quebec hospital diagnosed between 1990 and 2016. Read More

    IgG4 Expression in Primary Cutaneous Marginal Zone Lymphoma: A Multicenter Study.
    Appl Immunohistochem Mol Morphol 2017 Feb 1. Epub 2017 Feb 1.
    *Department of Dermatology ‡Harvard Medical School §Department of Pathology, Massachusetts General Hospital, Boston, MA †Kempf and Pfaltz, Histologische Diagnostik, Zürich, Switzerland ∥Dermatopathologie Friedrichshafen, Germany.
    Background: Primary cutaneous marginal zone lymphoma (PCMZL) is the second most common B-cell lymphoma of the skin. A recent study has demonstrated a strikingly high prevalence of immunoglobulin (Ig)G4 expression in PCMZL with plasmacytic differentiation.

    Objective: The objective was to investigate the incidence of IgG4 expression in PCMZL, and its correlation with clinical and immunophenotypic features. Read More

    B Cell Lymphoma Underlying Paraffinoma of Glabella.
    J Craniofac Surg 2017 Jan 30. Epub 2017 Jan 30.
    *Department of Plastic and Reconstructive Surgery †Department of Pathology, Haeundae Paik Hospital, College of Medicine, The Inje University, Busan, Republic of Korea.
    Soft tissue reactions to paraffin include inflammation, fibrosis, disfigurement, and granulomatous inflammation with foreign body giant cell reaction. The authors report the case of a 77-year-old woman with cutaneous marginal zone B cell lymphoma located on glabella, arising in association with underlying paraffinoma. While it is unclear whether the implant directly contributed to the development of lymphoma, this association has not been previously documented, prompting this report. Read More

    Primary Cutaneous Follicular Helper T-cell Lymphoma in a Patient With Neurofibromatosis Type 1: Case Report and Review of the Literature.
    Am J Dermatopathol 2017 Feb;39(2):134-139
    *Sunnybrook Health Science Centre, Division of Dermatology, University of Toronto, Toronto, Ontario; and †University Health Network, Toronto General Hospital, University of Toronto, Department of Pathology, Toronto, Ontario.
    Patients with neurofibromatosis type 1 (NF-1) have a well-known predisposition for certain types of malignancies, including lymphoproliferative disorders. Cutaneous T-cell lymphoma (CTCL) has been reported in patients with NF-1, although it is considered a rare entity in this subset of patients. Cutaneous follicular helper T-cell lymphoma (CTFHCL) is a recently emerged rare subtype of CTCL with peculiar clinical and histopathological features and represents a diagnostic and therapeutic challenge. Read More

    Primary cutaneous diffuse large B-cell lymphoma presenting as chronic non-healing ulcer.
    Int Wound J 2017 Jan 24. Epub 2017 Jan 24.
    Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, FL, USA.
    Primary cutaneous diffuse large B-cell lymphoma is an uncommon and aggressive lymphoproliferative disorder with a rapid growth rate and dismal prognosis. We present the case of a 91-year-old female with an unusual manifestation of primary cutaneous diffuse large B-cell lymphoma, mimicking other more prevalent diseases like chronic non-healing venous ulceration. Dermatopathologic evaluation rendered the correct diagnosis. Read More

    Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union.
    Orphanet J Rare Dis 2017 Jan 21;12(1):17. Epub 2017 Jan 21.
    Universidade de Lisboa, Faculdade de Farmácia, Avenida Professor Gama Pinto, 1649-003, Lisboa, Portugal.
    The Committee for Orphan Medicinal Products (COMP) evaluates prevalence of rare conditions as one of the criteria for granting an orphan designation with a prevalence threshold of 5 in 10.000. At the time of Marketing Authorisation (MA) these criteria are reassessed to ensure they are still met. Read More

    A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.
    Leuk Lymphoma 2017 Jun 19;58(6):1349-1357. Epub 2017 Jan 19.
    a Massey Cancer Center, Virginia Commonwealth University , Richmond , VA , USA.
    A phase 1 study was conducted to determine the dose-limiting toxicities and maximum-tolerated dose (MTD) for bortezomib followed by romidepsin on days 1, 8, and 15 in patients with relapsed/refractory CLL/SLL or B- or T-cell lymphoma. Eighteen treated patients were evaluable for response. The MTD was 1. Read More

    Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma.
    Semin Diagn Pathol 2017 Jan 2;34(1):85-98. Epub 2016 Dec 2.
    Department of Pathology, University of California San Francisco, USA; Department of Dermatology, University of California San Francisco, USA. Electronic address:
    In this review, we present clinical features and detailed histopathologic, immunologic, and molecular information regarding primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type which together represent two of the three most common types of primary cutaneous B-cell lymphoma recognized in the current WHO classification system.(1,2) Overall, B-cell lymphomas represent 19-27% of primary cutaneous lymphomas in most large European and American studies(3-6) and together, primary cutaneous follicle center lymphoma and primary cutaneous diffuse large B-cell lymphoma, leg type account for approximately 2/3 to ¾ of these cases.(5,7-11) Both subtypes can contain a high content of large B-lymphocytes, although most cases of primary cutaneous follicle center lymphomas exhibit a range in cell size and cytology. Read More

    A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders.
    Semin Diagn Pathol 2017 Jan 29;34(1):22-35. Epub 2016 Nov 29.
    Kempf und Pfaltz, Histologische Diagnostik, Zürich, Switzerland; Department of Dermatology, University Hospital Zurich, CH-8091, Zurich, Switzerland. Electronic address:
    Cutaneous CD30+ T-cell lymphoproliferative disorders (CD30+ T-LPD) represent a spectrum encompassing lymphomatoid papulosis (LyP), primary cutaneous anaplastic large-cell lymphoma (pcALCL) and borderline lesions. They share the expression of CD30 as a common phenotypic marker. They differ however in their clinical presentation, the histological features and clinical course. Read More

    Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy.
    J Dtsch Dermatol Ges 2016 Dec;14(12):1207-1224
    Department of Dermatology, Venereology, and Allergology, University Hospital Würzburg, Germany.
    Cutaneous B-cell lymphomas (CBCLs) comprise a group of mature lymphoproliferative B-cell disorders that primarily affect the skin. Characterized by great biological and clinical variability among its various subtypes, CBCLs fundamentally differ from primary nodal or systemic B-cell lymphomas. Given their uncomplicated course and excellent prognosis, lymphoma classifications rank primary cutaneous marginal zone lymphoma (PCMZL) and primary cutaneous follicle center lymphoma (PCFCL) as indolent CBCLs. Read More

    Cutaneous EBV-related lymphoproliferative disorders.
    Semin Diagn Pathol 2017 Jan 7;34(1):60-75. Epub 2016 Dec 7.
    Hematopathology, National Cancer Institute (NCI), Bethesda, MD, USA.
    This article will focus on the cutaneous lymphoproliferative disorders associated with EBV, with an emphasis on the upcoming changes in the revised 4th Edition of the WHO classification of tumors of the hematopoietic system, many of which deal with cutaneous disorders derived from NK-cells or T-cells. Extranodal NK/T-cell lymphoma usually presents in the upper aerodigestive tract, but can involve the skin secondarily. EBV-associated T- and NK-cell lymphoproliferative disorders (LPD) in the pediatric age group include the systemic diseases, chronic active EBV infection (CAEBV) and systemic EBV+ T-cell lymphoma of childhood. Read More

    Cutaneous marginal zone lymphomas.
    Semin Diagn Pathol 2017 Jan 29;34(1):76-84. Epub 2016 Nov 29.
    Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, UPMC-Presbyterian, G-335, 200 Lothrop Street, Pittsburgh, PA 15213. Electronic address:
    Primary cutaneous marginal zone lymphoma (CMZL) is one of the major primary B-cell lymphomas of skin. Two types are recognized: a more common class-chain switched CMZL, and a much less common IgM+ CMZL. The extremely indolent course, together with other features distinct from most other MALT lymphomas, has led some to question whether at least the class-switched cases should be considered an overt lymphoma. Read More

    Past, present and future of cutaneous lymphomas.
    Semin Diagn Pathol 2017 Jan 28;34(1):3-14. Epub 2016 Nov 28.
    Research Unit Dermatopathology, Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, 8036 Graz, Austria. Electronic address:
    Primary cutaneous lymphomas represent a broad group of diseases with different clinical, histopathological, phenotypic, molecular, and prognostic features. All cutaneous lymphomas share the same tropism of neoplastic lymphocytes for the skin, but precise classification is paramount for proper management of the patients. Primary cutaneous lymphomas are classified according to the schemes proposed by the European Organization for Research and Treatment of Cancer (EORTC)-Cutaneous Lymphomas Task Force together with the World Health Organization (WHO) in 2005, and the WHO classification of 2008 with the 2016 update. Read More

    Diffuse Subcutaneous Fat Involvement in a Marginal Zone Lymphoma.
    Clin Nucl Med 2017 Feb;42(2):129-130
    From the *Nuclear Medicine Department, Hospices Civils de Lyon, Lyon; †Equipe Mixte de Recherche 3738, Claude Bernard Lyon 1 University; ‡Hematology Department, Hospices Civils de Lyon, Lyon; and §Faculty of Medicine Lyon Sud, Claude Bernard Lyon 1 University.
    Marginal zone lymphoma (MZL) is usually considered not avid for FDG. We report a case of a 57-year-old man with an MZL suspected for transformation. FDG-PET/CT showed a diffuse atypical involvement of subcutaneous fat, without sign suggestive for a transformation. Read More

    Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.
    Expert Rev Hematol 2017 Jan 21;10(1):29-37. Epub 2016 Dec 21.
    a Hematology & Oncology , University of Alabama at Birmingham , Birmingham , AL , USA.
    Introduction: CD30 is a cell surface receptor expressed in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), and many other lymphomas to a variable degree. It has been identified as an important therapeutic target in lymphoma. Areas covered: CD30 testing is essential in diagnosis of classical HL and ALCL, and expression can also be seen in other lymphoma subtypes. Read More

    A Clinicopathological Analysis of Primary Cutaneous Lymphomas: A 6-year Observational Study at a Tertiary Care Center of South India.
    Indian J Dermatol 2016 Nov-Dec;61(6):608-617
    Department of Pathology, Government Medical College, Kozhikode, Kerala, India.
    Background: Little data are available concerning clinical and pathological patterns of cutaneous lymphomas in India.

    Aim: To analyze the clinical and histopathological characteristics of cutaneous lymphomas in Indian patients.

    Materials And Methods: This is a single-center, prospective, observational study carried out from January 1, 2010, to December 31, 2015. Read More

    Lymphoma of the eyelid.
    Surv Ophthalmol 2017 May - Jun;62(3):312-331. Epub 2016 Nov 26.
    Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Ophthalmology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. Electronic address:
    Lymphoma of the eyelid constitutes 5% of ocular adnexal lymphoma. In previously published cases, 56% of lymphomas of the eyelid are of B-cell origin and 44% are of T-cell origin. The most frequent B-cell lymphomas are extranodal marginal zone lymphoma (27 cases-14%) and diffuse large B-cell lymphoma (18 cases-9%). Read More

    Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.
    Leukemia 2016 Dec 16. Epub 2016 Dec 16.
    Division of Oncology Research, Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA.
    Histone deacetylase (HDAC) inhibitors, which are approved for the treatment of cutaneous T-cell lymphoma and multiple myeloma, are undergoing evaluation in other lymphoid neoplasms. How they kill susceptible cells is incompletely understood. Here, we show that trichostatin A, romidepsin and panobinostat induce apoptosis across a panel of malignant B cell lines, including lines that are intrinsically resistant to bortezomib, etoposide, cytarabine and BH3 mimetics. Read More

    MYD88 mutations in a distinct type of cutaneous marginal zone lymphoma with a non-class switched IgM-immunophenotype.
    Br J Dermatol 2016 Nov 18. Epub 2016 Nov 18.
    Institute of Pathology, Comprehensive Cancer Center, University of Wuerzburg, Germany.
    Somatic mutations in the MYD88 gene are involved in the molecular pathogenesis of different subtypes of Non-Hodgkin B-cell lymphomas such as diffuse large B-cell lymphoma, lymphoplasmacytic lymphoma and Waldenstrom's macroglobulinemia(1) . Albeit with much lower frequency, the key driver mutation MYD88 (c.794T>C, p. Read More

    Proteomic Approaches to Biomarker Discovery in Cutaneous T-Cell Lymphoma.
    Dis Markers 2016 16;2016:9602472. Epub 2016 Oct 16.
    Dermatology Research Laboratory, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania; Department of Dermatology, Carol Medical Center, 020915 Bucharest, Romania.
    Cutaneous T-cell lymphoma (CTCL) is the most frequently encountered type of skin lymphoma in humans. CTCL encompasses multiple variants, but the most common types are mycosis fungoides (MF) and Sezary syndrome (SS). While most cases of MF run a mild course over a period of many years, other subtypes of CTCL are very aggressive. Read More

    Pattern of skin cancer among Saudi patients attending a tertiary care center in Dhahran, Eastern Province of Saudi Arabia. A 20-year retrospective study.
    Int J Dermatol 2016 Dec 3;55(12):1396-1401. Epub 2016 Jun 3.
    Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
    Skin cancer is the ninth most common malignancy in Saudi Arabia. It represented 3.2% of all newly diagnosed cancer cases in the year 2010. Read More

    Occurrence of lymphoma in non-gonadal organ during pregnancy: a report on four cases and literature review.
    Cancer Biol Med 2016 Sep;13(3):399-403
    Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
    Lymphoma rarely occurs during pregnancy, making this condition difficult to define. Lymphomas that occur in reproductive organs during pregnancy exhibit unique clinical characteristics. Among the limited cases, non-Hodgkin's lymphoma (NHL) shows a considerably higher incidence rate than Hodgkin's lymphoma (HL); NHL also displays clinical characteristics, such as high aggressiveness, advanced stage, and poor outcome. Read More

    De Novo CD5-Positive Diffuse Large B-Cell Lymphoma: Report of a Case Presenting With Cutaneous Involvement and Featuring Extensive Intravascular Dissemination on Postmortem Examination.
    Int J Surg Pathol 2016 Dec 17;24(8):763-768. Epub 2016 Jul 17.
    Department of Pathology, Hospital Universitario Fundación Jiménez Díaz, Madrid.
    De novo CD5-positive diffuse large B-cell lymphoma (DLBCL) represents 10% of DLBCLs and is frequently associated with an aggressive clinical course and poor response to chemotherapy. We report a case of an 84-year old man who presented with cutaneous lesions, malaise, and B-symptoms. A skin biopsy revealed neoplastic cells within the lumen of dermal vessels. Read More

    The role of 18F-FDG PET and PET/CT in the evaluation of primary cutaneous lymphoma.
    Nucl Med Commun 2017 Feb;38(2):106-116
    Departments of aNuclear Medicine bRadiology, Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
    Primary cutaneous lymphoma (PCL) is the second most common type of extranodal non-Hodgkin lymphoma, including both cutaneous T-cell and B-cell lymphomas. PCL comprises numerous subtypes and thus has myriad clinical presentations in the skin and subcutaneous tissues. Accurate classification and staging are important for making treatment recommendations for PCL and will further impact patient prognosis significantly. Read More

    Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.
    Cancer Med 2016 Oct 26;5(10):2740-2755. Epub 2016 Sep 26.
    Unit of Anatomic Pathology, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
    Categorization of primary cutaneous B-cell lymphomas (PCBCL) other than marginal zone (MZL) represents a diagnostic challenge with relevant prognostic implications. The 2008 WHO lymphoma classification recognizes only primary cutaneous follicular center cell lymphoma (PCFCCL) and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT), whereas the previous 2005 WHO/EORTC classification also included an intermediate form, namely PCDLBCL, other. We conducted a retrospective, multicentric, consensus-based revision of the clinicopathologic characteristics of 161 cases of PCBCL other than MZL. Read More

    A case report of mantle cell lymphoma manifesting as a foot lesion.
    Tumori 2016 Nov 11;102(Suppl. 2). Epub 2016 Nov 11.
    Wakefield Clinical Laboratories, Department of Pathology, Montefiore Medical Center, Bronx, New York - USA.
    Introduction: Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin lymphoma that most commonly affects men above the age of 60 years. The disease is called MCL because the tumor cells originate from the mantle zone of the lymph node. The most commonly affected sites are the lymph nodes, bone marrow, gastrointestinal tract, Waldeyer's ring and rarely the skin, breast and central nervous system. Read More

    Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report.
    Medicine (Baltimore) 2016 Oct;95(43):e4796
    Department of Dermatology and Allergology, Insitute of Pathology "Georg Schmorl", Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany.
    Background: Cutaneous composite lymphomas are very rare. Their treatment depends upon the different contributing lymphoma entities. Peripheral T-cell lymphoma, not otherwise specified, (PTCL-NOS) represents an aggressive lymphoma subtype. Read More

    Cyclin D1 expression in peripheral T-cell lymphomas.
    Mod Pathol 2016 Nov 29;29(11):1306-1312. Epub 2016 Jul 29.
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
    Cyclin D1 is an important regulator of the cell cycle and overexpression of this protein by immunohistochemistry is characteristically seen in mantle cell lymphoma and other B-cell neoplasms. However, little is known about the expression of this protein in T-cell lymphomas. Cyclin-dependent kinase pathway inhibitors are in development, therefore identifying cyclin D1-positive T-cell lymphomas may provide a therapeutic target in a disease where novel treatments are urgently needed. Read More

    Rare association of cystic squamous cell carcinoma and small lymphocytic B cell lymphoma: successful surgical approach.
    Wien Med Wochenschr 2017 Apr 8;167(5-6):104-109. Epub 2016 Sep 8.
    "Onkoderma"-Policlinic for Dermatology and Dermatologic Surgery, General Skobelev 26 blvd., Sofia, Bulgaria.
    Non-melanoma skin cancer is the most common type of cutaneous neoplasm worldwide. While basal cell carcinoma is the most common tumor, squamous cell carcinoma (SCC) causes higher morbidity and has a risk of metastatic spread, depending on immune status, tumor size, and desmoplastic growth. We reported the case of a 77 year old male patient with retroauricular tumor, which started growing 3 years ago and was excised, buth relapsed three times. Read More

    Cutaneous metastasis of inflammatory breast carcinoma mimicking an erythema annulare centrifugum: a sign of locally recurrent cancer.
    Clin Exp Dermatol 2016 Dec 20;41(8):906-910. Epub 2016 Oct 20.
    Department of Oncology, Hospital Casa de Salud, Valencia, Spain.
    Erythema annulare centrifugum (EAC) is a clinical reaction pattern that includes lupus erythematosus, spongiotic dermatitis (particularly pityriasis rosea), pseudolymphoma and cutaneous B-cell lymphoma. However, it can be the result of cutaneous metastasis by an internal carcinoma. We present the case of a 38-year-old woman with bilateral inflammatory breast cancer following multimodal therapy. Read More

    An Aggressive Primary Cutaneous Follicle Center Lymphoma With c-MYC Translocation and CDKN2A (9p21) Deletion: A Case Report and Review of the Literature.
    Am J Dermatopathol 2017 Mar;39(3):e44-e49
    Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY.
    Diffuse large cell B-cell lymphoma of the skin is most commonly represented by diffuse large cell variants of primary cutaneous follicle center lymphoma and the leg-type lymphoma. In a minority of cases, the infiltrates are an expression of stage 4 disease of established extracutaneous B-cell lymphoma. We describe 1 female patient 85 years of age with an aggressive form of primary cutaneous B-cell lymphoma manifesting in multiple firm erythematous indurated solid nodules 1-2 cm each symmetrically on the face periorbitally and on the upper extremities bilaterally. Read More

    1 OF 49